We are live on ! Find out more
IMDX

Insight Molecular Diagnostics
IMDX

54 hedge funds and large institutions have $39.8M invested in Insight Molecular Diagnostics in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 14 increasing their positions, 15 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

178% more call options, than puts

Call options by funds: $25K | Put options by funds: $9K

29% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 14

8% more funds holding

Funds holding: 50 → 54 (+4)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.02% less ownership

Funds ownership: 1.55% → 1.54% (-0.02%)

7% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 15

38% less capital invested

Capital invested by funds: $63.7M → $39.8M (-$23.9M)

Holders
54
Holders Change
+4
Holders Change %
+8%
% of All Funds
1.17%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
18
Increased
14
Reduced
15
Closed
14
Calls
$25K
Puts
$9K
Net Calls
+$16K
Net Calls Change
+$16K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$5.94M
2
State Street
State Street
Massachusetts
+$1.46M
3
MS
Maven Securities
Jersey
+$896K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$651K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$533K

Top Sellers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
-$5.09M
2
SSA
Schonfeld Strategic Advisors
New York
-$2.82M
3
Deutsche Bank
Deutsche Bank
Germany
-$717K
4
EI
EAM Investors
California
-$670K
5
Millennium Management
Millennium Management
New York
-$579K
Name Holding Trade Value Shares
Change 		Change in
Stake
EI
51
EAM Investors
California
– -$670K -8,482 Closed
Renaissance Technologies
52
Renaissance Technologies
New York
– -$538K -6,810 Closed
SIM
53
Spark Investment Management
New York
– -$159K -2,015 Closed
BFM
54
Boothbay Fund Management
New York
– -$126K -1,600 Closed
DWM
55
Destination Wealth Management
California
– -$117K -1,483 Closed
VF
56
Virtu Financial
New York
– -$114K -1,444 Closed
PCM
57
Perkins Capital Management
Minnesota
– -$99K -1,250 Closed
WMSA
58
Weiss Multi-Strategy Advisers
New York
– -$99K -1,250 Closed
JT
59
Jump Trading
Illinois
– -$78K -992 Closed
ECM
60
ExodusPoint Capital Management
New York
– -$41K -515 Closed
Marshall Wace
61
Marshall Wace
United Kingdom
– -$16K -198 Closed
TRCT
62
Tower Research Capital (TRC)
New York
– -$11.9K -143 -97%
MWNA
63
Marshall Wace North America
New York
– -$3K -43 Closed
PCM
64
Prelude Capital Management
New York
– -$1K -16 Closed
Simplex Trading
65
Simplex Trading
Illinois
– -$499 -6 -38%
HPC
66
HM Payson & Co
Maine
– +$582 +7 New
1 2
3

IMDX Hedge Fund Activity: Q2 2019 in Review

54 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q2 2019, worth a combined $39.8M — down 38% from $63.7M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new IMDX positions and 14 closed out — a net gain of 4 holders — while 14 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $5.94M. The largest seller was RTW Investments, exiting entirely with an estimated $5.09M sold.

  • 54 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q2 2019, up from 50 in Q1 2019.
  • Funds reported $39.8M of Insight Molecular Diagnostics stock for Q2 2019, down 38% quarter-over-quarter.
  • 18 funds opened new Insight Molecular Diagnostics positions in Q2 2019 and 14 closed out, a net change of +4 holders.
  • The largest Insight Molecular Diagnostics buyer in Q2 2019 was BlackRock, an estimated $5.94M added.
  • The largest Insight Molecular Diagnostics seller in Q2 2019 was RTW Investments, an estimated $5.09M sold.

Based on aggregated 13F filings for Q2 2019.